Skip to main content

Evaluation of the efficacy and of the antiviral activity of T-705 (favipiravir) during Ebola virus infection in non-human primates humans

Objective

The ongoing Ebola outbreak in West Africa is the largest and deadliest the world has ever seen. In September 2014, the number of EBOV cases exceeded the total of all cases from previous known outbreaks. Further, this public health crisis shifted into a complex emergency, with significant, social, economic, humanitarian, political and security dimensions. Till date, no effective medicine has been proven to be effective against EBOV. As a result, it is immensely difficult to mitigate the current outbreak as well as prevent further outbreaks in this region. On Sept 4-5 2014, the WHO gathered expertise on experimental therapies and vaccines and their role in containing the Ebola outbreak in West Africa. During this consultation, experts identified several therapeutic and vaccine interventions that should be the focus of priority evaluation. Among these candidates is the existing antiviral drug Favipiravir, that has proven activity against many RNA viruses in vivo and in vitro including Ebola. Favipiravir is known to inhibit viral gene replication within infected cells to prevent propagation among which it inhibits viral gene replication within infected cells to prevent propagation. Hence, Favipiravir is currently aimed as a curative option in severe pandemic flue. Furthermore, there is currently enough stock of Favipiravir to even treat more than 20.000 patients, and the producer of Favipiravir, Toyoma Chemical/Fujifilm in Japan is willing to rapidly upscale the production of this drug. This drug has been extensively tested in humans and approved in Japan for treatment and prevention of influenza. The drug has shown an excellent safety profile in more than 2000 patients tested and no major adverse effect were reported. The current crisis requires both an immediate response to treat patients and prevent the further spread of the epidemic, as well as long term commitment in the complex sociocultural context. REACTION! will address both needs.

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution
€ 1 240 726,00
Address
Rue De Tolbiac 101
75654 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Other funding
€ 67 500,00

Participants (12)

CENTRE TECHNOLOGIQUE NOUVELLE-AQUITAINE COMPOSITES & MATERIAUX AVANCES
France
Net EU contribution
€ 477 262,00
Address
Batiment Cheminnov Enscbp Av Pey Berland 16
33600 Pessac

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Nouvelle-Aquitaine Aquitaine Gironde
Activity type
Research Organisations
Other funding
€ 0,00
BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN
Germany
Net EU contribution
€ 64 250,00
Address
Bernhard Nocht Strasse 74
20359 Hamburg

See on map

Region
Hamburg Hamburg Hamburg
Activity type
Research Organisations
Other funding
€ 11 250,00
INSTITUT PASTEUR
France
Net EU contribution
€ 74 025,00
Address
Rue Du Docteur Roux 25-28
75724 Paris Cedex 15

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Other funding
€ 23 437,50
ECOLE NORMALE SUPERIEURE DE LYON
France
Net EU contribution
€ 142 500,00
Address
Parvis Rene Descartes 15
69342 Lyon

See on map

Region
Auvergne-Rhône-Alpes Rhône-Alpes Rhône
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
UNIVERSITE D'AIX MARSEILLE
France
Net EU contribution
€ 88 500,00
Address
Boulevard Charles Livon 58 Le Pharo
13284 Marseille

See on map

Region
Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône
Activity type
Higher or Secondary Education Establishments
Other funding
€ 31 250,00
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Germany
Net EU contribution
€ 86 250,00
Address
Seminarstrasse 2
69117 Heidelberg

See on map

Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
DRUG DISCOVERY FACTORY BV
Netherlands
Net EU contribution
€ 127 062,50
Address
Joop Geesinkweg 167
1114 AB Amsterdam Duivendrecht

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
West-Nederland Zuid-Holland Agglomeratie ’s-Gravenhage
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00
UNIVERSITEIT VAN AMSTERDAM

Participation ended

Netherlands
Net EU contribution
€ 72 359,00
Address
Spui 21
1012WX Amsterdam
Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Higher or Secondary Education Establishments
Other funding
€ 13 831,89
UNIVERSITEIT UTRECHT
Netherlands
Net EU contribution
€ 4 250,00
Address
Heidelberglaan 8
3584 CS Utrecht

See on map

Region
West-Nederland Utrecht Utrecht
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
UNIVERSITE CHEIKH ANTA DIOP DE DAKAR
Senegal
Net EU contribution
€ 134 375,00
Address
Avenue Martin Luther King
- Dakar Fann

See on map

Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
Department of Health
United Kingdom
Net EU contribution
€ 64 250,00
Address
Quarry House, Quarry Hill
LS2 7UE Leeds

See on map

Region
Yorkshire and the Humber West Yorkshire Leeds
Activity type
Research Organisations
Other funding
€ 5 625,00
FONDATION POUR L INSTITUT DE HAUTES ETUDES INTERNATIONALES ET DU DEVELOPPEMENT
Switzerland
Net EU contribution
€ 0,00
Address
Maison De La Paix Chemin Eugene Rigot 2
1202 Geneve

See on map

Region
Schweiz/Suisse/Svizzera Région lémanique Genève
Activity type
Higher or Secondary Education Establishments
Other funding
€ 27 016,00